PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515507
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515507
Non-Viral Transfection Reagents and Systems Market size was valued at USD 786.23 Million in 2023, expanding at a CAGR of 8.2% from 2024 to 2032.
Non-viral transfection reagents are substances used in molecular biology and biotechnology to deliver genetic material (such as DNA or RNA) into cells without the use of viral vectors. They facilitate the introduction of nucleic acids into cells for various purposes, including gene expression studies, protein production, gene therapy, and genome editing.
Non-Viral Transfection Reagents and Systems Market- Market Dynamics
The need for Non-Viral Transfection Reagents in clinical settings is fueling their market growth.
Non-viral transfection is a compelling alternative to established methods, offering distinct advantages. These advantages include expedited timelines, enhanced biological efficiency, reduced cytotoxicity, and the ability to deliver a wider variety of nucleic acids. The pivotal role of non-viral transfection reagents in clinical applications is a key driver of their growth. These reagents facilitate the delivery of therapeutic nucleic acids, such as siRNA, miRNA, and DNA plasmids encoding therapeutic proteins or CRISPR/Cas9 genome editing tools. This capability paves the way for the development of innovative gene therapies for a broad spectrum of conditions, including genetic disorders, cancers, and infectious diseases.
The current landscape reflects a surge in activity by numerous companies actively developing advanced non-viral transfection reagents and systems. For example, recently, BioCentriq, a cell therapy expert, and Kytopen, an MIT startup, teamed up to develop innovative cell therapy manufacturing technology.
Non-Viral Transfection Reagents and Systems Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.2% over the forecast period (2024-2032)
Based on Type segmentation, non-viral transfection reagents were predicted to show maximum market share in the year 2023
Based on Application segmentation, Research Applications was the leading type in 2023
Based on End User segmentation, Pharmaceutical Companies were the leading type in 2023
Based on region, Asia-Pacific was the leading revenue generator in 2023
The Global Non-Viral Transfection Reagents and Systems Market is segmented based on Type, Application, End User, and Region.
The market is divided into three categories based on Type: Non-Viral Transfection Reagents, Electroporation-based Transfection Systems and Other Non-Viral Transfection Systems. Electroporation involves applying electrical pulses to cells in the presence of nucleic acids, creating temporary pores in the cell membrane through which genetic material can enter. Electroporation is known for its high transfection efficiency and is particularly effective for difficult-to-transfect cells and primary cells. It can be used for transient and stable transfection but requires specialized equipment and optimization for different cell types.
The market is divided into two categories based on Application: Clinical and Research. Research based on non-viral transfection reagents spans a wide spectrum of biological and biomedical fields. Such as in gene function studies, researchers employ non-viral transfection reagents to introduce specific genes or regulatory elements into cells. This allows them to study gene expression patterns, regulatory mechanisms, and the roles of genes in various cellular processes.
Non-Viral Transfection Reagents and Systems Market- Geographical Insights
The biotechnology and pharmaceutical industries in the Asia-Pacific region are expanding swiftly due to substantial investments in research and development. This growth is particularly pronounced in countries such as China, Japan, and South Korea. As a result, there is an increasing need for non-viral transfection reagents. These reagents are crucial for delivering genetic material precisely to target cells and supporting the development of gene therapy and gene editing technologies. Moreover, the rising prevalence of genetic disorders is contributing to the heightened demand for these reagents in the region's biomedical research and therapeutic advancements. For instance, the diverse makeup of Pakistan's population, characterized by significant levels of consanguinity, contributes to the higher prevalence of genetic disorders cases.
Some of the key players in the Non-Viral Transfection Reagent and Systems Market are Thermo Fisher Scientific, Bio-Rad Laboratories, Inovio Pharmaceuticals, and MaxCyte. Each brings unique technologies and expertise to advance research and therapeutic applications involving genetic manipulation and cell engineering. For example, MaxCyte, is offering scalable solutions for transient and stable transfection of primary cells, stem cells, and cell lines. MaxCyte's systems are valued for their high transfection efficiency, scalability, and applicability in research and clinical settings.
Bio-Rad Laboratories specialises in electroporation-based transfection systems, which offer high efficiency for delivering nucleic acids into cells by applying electrical pulses. Bio-Rad's systems are widely used for difficult-to-transfect cells and primary cells in research and biopharmaceutical applications.
In Sept 2023, A new enterprise stemming from the University of Nottingham, dedicated to advancing a dry powder gene therapy formulation for bone graft augmentation, along with its partner, the University of Nottingham, has been granted £995,000 by Innovate UK, the UK's innovation agency.
In August 2023, Altogen Biosystems introduced a focused reagent designed to transport biomolecules to the lungs for treating patients with pulmonary diseases. The drug has safely and effectively transported small molecules, DNA, RNA, and proteins to the lungs.
GLOBAL NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Thermo Fisher Scientific (TFS)
Lonza Group
Imunon (Formerly known as Celsion)
Promega Corporation
Altogen Biosystems
Mirus Bio LLC
Genprex
Polyplus-Transfection SA
Bio-Rad Laboratories
MaxCyte
MilliporeSigma
Qiagen
Takara Bio